Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced a global license agreement with Roche and Genentech, a member of the Roche Group (Genentech), for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ).
- The agreement provides an optimal infrastructure for the further development of vixarelimab.
- Under the terms of the global license agreement, Kiniksa will receive $100 million in upfront and near-term payments, and is eligible to receive up to approximately $600 million in certain clinical, regulatory, and sales-based milestones, before fulfilling upstream financial obligations.
- Kiniksa has completed screening patients for the Phase 2b clinical trial of vixarelimab in prurigo nodularis.
- ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.